AbbVie to Buy Immunology Drugmaker Apogee for $10.9 Billion

AbbVie (ABBV) announced it will acquire Apogee Therapeutics, a biotech focused on immunology, in a cash deal valued at $10.9 billion. The acquisition adds an experimental drug for moderate to severe atopic dermatitis (eczema), strengthening AbbVie's core immunology franchise.

Deal Details

• Value: $10.9 billion in cash.
• Target: Apogee Therapeutics.
• Key Asset: An experimental drug for moderate to severe atopic dermatitis.
• Expected Close: Not yet announced.

Rationale

The deal is part of AbbVie's strategy to bolster its immunology pipeline as Humira faces biosimilar competition. Apogee's drug, which has shown promising Phase 2 results, could fill a gap in AbbVie's portfolio.

Regulatory Challenges

The deal will likely face antitrust review in the U.S. and Europe. However, given limited product overlap, significant hurdles are not expected.

Impact on Stocks

• AbbVie (ABBV): May face short-term pressure due to the cash outlay, but could benefit long-term from pipeline diversification.
• Regeneron (REGN): Could be negatively impacted if Apogee's drug competes with its eczema treatment Dupixent.